Belite Bio (BLTE) Cash & Equivalents (2021 - 2025)

Belite Bio's Cash & Equivalents history runs 5 years deep, the most recent figure standing at $337.3 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 964.78% year-over-year to $337.3 million; the TTM figure through Dec 2025 stood at $337.3 million (up 964.78% YoY), while the FY2025 annual figure was $337.3 million, up 964.78% from the prior year.
• Cash & Equivalents was $337.3 million for Q4 2025 at Belite Bio, up from $31.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $337.3 million in Q4 2025 to a low of $17.3 million in Q4 2021.
• Historically, Cash & Equivalents has averaged $90.9 million across 5 years, with a median of $42.1 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 64.07% in 2024, then jumped 964.78% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $17.3 million in 2021, then surged by 142.67% to $42.1 million in 2022, then jumped by 109.45% to $88.2 million in 2023, then plunged by 64.07% to $31.7 million in 2024, then surged by 964.78% to $337.3 million in 2025.
• The last three Cash & Equivalents figures came in at $337.3 million (Q4 2025), $31.7 million (Q3 2025), and $31.7 million (Q4 2024), per Business Quant data.